Tumor-Size-Based Measurements as Endpoint in Cancer Clinical Trials
June 15, 2017
Since the early days of clinical cancer research, given the expected direct cytotoxicity of chemotherapy, tumor shrinkage has been used as a proxy for anticancer activity. IDDI organized a webinar on the use of endpoints based on tumor measurements in cancer clinical trial.
In this webinar, the speaker provided:
- An overview of the use of endpoints based on tumor measurements in cancer clinical trials.
- The definitions of the traditional and novel response-based endpoints, discussing their pros and cons.
- Several examples, including results of their own work related, in particular, to modeling tumor-size changes and use of the depth of response as a surrogate for overall survival in colorectal cancer trials
TO ACCESS THE PRESENTATION OF THIS ON-DEMAND WEBINAR, PLEASE FILL OUT THE FORM BELOW